CA2306953A1 - Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase - Google Patents

Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase Download PDF

Info

Publication number
CA2306953A1
CA2306953A1 CA002306953A CA2306953A CA2306953A1 CA 2306953 A1 CA2306953 A1 CA 2306953A1 CA 002306953 A CA002306953 A CA 002306953A CA 2306953 A CA2306953 A CA 2306953A CA 2306953 A1 CA2306953 A1 CA 2306953A1
Authority
CA
Canada
Prior art keywords
amino acid
group
acid selected
scupa
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306953A
Other languages
English (en)
Inventor
Abd Al-Roof Higazi
Douglas Cines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2306953A1 publication Critical patent/CA2306953A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des compositions et à des procédés permettant de favoriser l'internalisation et la dégradation de l'activateur du plasminogène de type urokinase.
CA002306953A 1997-10-17 1998-10-15 Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase Abandoned CA2306953A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6227497P 1997-10-17 1997-10-17
US60/062,274 1997-10-17
PCT/US1998/021800 WO1999020295A1 (fr) 1997-10-17 1998-10-15 Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase

Publications (1)

Publication Number Publication Date
CA2306953A1 true CA2306953A1 (fr) 1999-04-29

Family

ID=22041403

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002306953A Abandoned CA2306953A1 (fr) 1997-10-17 1998-10-15 Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase

Country Status (5)

Country Link
EP (1) EP1030679A4 (fr)
JP (1) JP2001520200A (fr)
AU (1) AU739373B2 (fr)
CA (1) CA2306953A1 (fr)
WO (1) WO1999020295A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216847A1 (en) * 2000-10-26 2002-05-06 K.U. Leuven Research And Development Epitopes of pai-1
US20030211095A1 (en) * 2002-05-08 2003-11-13 Abd. Al-Roof Higazi Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
US7271143B1 (en) * 2001-07-10 2007-09-18 Thrombotech Ltd. Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
EP2468289A1 (fr) * 2007-07-24 2012-06-27 Thrombotech Ltd. Peptides dérivés d'un inhibiteur-1 d'activateur de plasminigène et utilisations correspondantes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3742997A1 (de) * 1987-12-18 1989-06-29 Behringwerke Ag Peptide, verfahren zu ihrer herstellung, ihre verwendung zur gewinnung von antikoerpern sowie deren verwendung zur blockierung der pai-1-aktivitaet menschlichen blutes
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
ZA928954B (en) * 1991-12-24 1993-05-19 Akzo Nv Peptides immunochemically reactive with antibodies directed against hepatitis non-A, non-B virus.
AU7137994A (en) * 1993-06-01 1994-12-20 Chiron Corporation Expression of urokinase plasminogen activator inhibitors
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US5674078A (en) * 1996-01-23 1997-10-07 The Whitaker Corporation Multi-directional interface header assembly

Also Published As

Publication number Publication date
WO1999020295A1 (fr) 1999-04-29
JP2001520200A (ja) 2001-10-30
EP1030679A4 (fr) 2003-03-05
AU1360999A (en) 1999-05-10
AU739373B2 (en) 2001-10-11
EP1030679A1 (fr) 2000-08-30

Similar Documents

Publication Publication Date Title
US6315995B1 (en) Methods for treating an ischemic disorder and improving stroke outcome
EP0328552B2 (fr) Polypeptides derives de la thrombine, compositions les contenant et procedes d'utilisation
JP6603207B2 (ja) ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
JP4986618B2 (ja) 通常の細胞保護活性を有するが抗凝固活性が低下した活性化プロテインｃ変異体
US8173595B2 (en) Methods and compositions for the inhibition of thrombus formation
US20220184189A1 (en) Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
US20050250688A1 (en) Methods for treating an ischemic disorder and improving stroke outcome
US7247611B2 (en) Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
AU739373B2 (en) Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6191103B1 (en) Methods for enhancing thrombolysis in a mammal
US8227412B2 (en) Bioactive parstatin peptides and methods of use
EP1448593B1 (fr) Peptides de l'alpha-fetoproteine et leurs utilisations
KR20010052371A (ko) 세린 프로테아제를 이용한 내피 세포 증식 억제 및안기오게네시스 조절을 위한 조성물 및 방법
US20090181057A1 (en) Methods and Compositions for the Inhibition of Thrombus Formation
US20020045589A1 (en) Hirulog-like peptide and gene therapy
US20070298024A1 (en) C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis
US20130035289A1 (en) Pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (prl)-growth hormone (gh)-placental lactogen (pl)-family protein
WO2010002453A2 (fr) L'inhibiteur c-1 évite l'activation non spécifique du plasminogène par un mutant de prourokinase sans entraver la fibrinolyse spécifique de la fibrine
JP2002535372A (ja) プラスミノーゲンクリングル４領域フラグメントおよび利用法
US7271143B1 (en) Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
IL165066A (en) Polypeptide having an inhibitory effect on vasoconstriction induced by plasminogen activators and pharmaceutical compositions containing the same
WO1994003488A1 (fr) Nouveau peptide
Crabtree Minicourse on Genetic Engineering by GR Crabtree
JPH09104637A (ja) 過凝固または低線溶状態およびその類縁疾患の予防治療剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued